TherapeuticsMD Inc (TXMD) Receives Consensus Recommendation of “Buy” from Analysts

Share on StockTwits

Shares of TherapeuticsMD Inc (NASDAQ:TXMD) have been given a consensus rating of “Buy” by the seven ratings firms that are currently covering the firm, MarketBeat reports. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 12-month price target among analysts that have covered the stock in the last year is $17.33.

Several research firms recently commented on TXMD. Zacks Investment Research raised shares of TherapeuticsMD from a “hold” rating to a “buy” rating and set a $6.25 target price for the company in a research note on Wednesday, October 17th. BidaskClub raised shares of TherapeuticsMD from a “sell” rating to a “hold” rating in a research note on Tuesday, February 5th. Cantor Fitzgerald set a $27.00 target price on shares of TherapeuticsMD and gave the company a “buy” rating in a research note on Sunday, October 14th. Finally, ValuEngine lowered shares of TherapeuticsMD from a “buy” rating to a “hold” rating in a research note on Monday, October 29th.

Shares of NASDAQ:TXMD traded up $0.07 during trading on Wednesday, reaching $5.30. The company had a trading volume of 54,255 shares, compared to its average volume of 2,480,436. TherapeuticsMD has a twelve month low of $3.51 and a twelve month high of $7.66. The firm has a market cap of $1.24 billion, a P/E ratio of -14.38 and a beta of 2.06. The company has a current ratio of 7.23, a quick ratio of 7.15 and a debt-to-equity ratio of 0.55.

In related news, CEO Robert G. Finizio sold 184,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 13th. The shares were sold at an average price of $4.77, for a total value of $877,680.00. Following the completion of the sale, the chief executive officer now owns 18,485,559 shares in the company, valued at approximately $88,176,116.43. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Brian Bernick sold 182,800 shares of the company’s stock in a transaction that occurred on Tuesday, November 20th. The shares were sold at an average price of $4.74, for a total transaction of $866,472.00. Following the completion of the sale, the director now owns 242,000 shares of the company’s stock, valued at approximately $1,147,080. The disclosure for this sale can be found here. In the last 90 days, insiders sold 2,578,475 shares of company stock valued at $11,847,963. 22.85% of the stock is owned by insiders.

A number of institutional investors have recently added to or reduced their stakes in TXMD. We Are One Seven LLC acquired a new position in TherapeuticsMD in the 4th quarter valued at approximately $26,000. Dfpg Investments Inc. acquired a new position in TherapeuticsMD in the 4th quarter valued at approximately $38,000. Creative Planning acquired a new position in TherapeuticsMD in the 4th quarter valued at approximately $63,000. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in TherapeuticsMD by 26.1% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 17,648 shares of the company’s stock valued at $67,000 after buying an additional 3,649 shares during the period. Finally, Stevens Capital Management LP acquired a new position in TherapeuticsMD in the 3rd quarter valued at approximately $101,000. Hedge funds and other institutional investors own 73.16% of the company’s stock.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a women's health care product company. Its pipeline of hormone therapy drug candidates include TX-001HR, a combination of estradiol and progesterone drug candidate under clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause; TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil; and TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy in post-menopausal women with vaginal linings that do not receive enough estrogen.

Recommended Story: How to Calculate Compound Annual Growth Rate (CAGR)

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply